Related Experiment Videos
[Pharmacokinetics of a new slow-release theophylline preparation in asthmatic children]
Insights
This study found that a new micronized slow-release theophylline preparation showed similar pharmacokinetic profiles to a known product in children with asthma. The new theophylline formulation offers a safer alternative due to reduced erratic behavior.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Respiratory Medicine
Background:
- Theophylline is a bronchodilator used for asthma management.
- Slow-release theophylline formulations aim to improve patient compliance and reduce side effects.
- A new micronized slow-release theophylline preparation has been developed for pediatric use.
Purpose of the Study:
- To compare the pharmacokinetics of a new micronized slow-release theophylline preparation with a known formulation.
- To evaluate the safety and efficacy of the new theophylline product in pediatric asthma patients.
Main Methods:
- A single oral dose of 10 mg/kg of either the known or micronized theophylline preparation was administered.
- Two groups of fifteen pediatric asthma patients (under ten years of age) were studied.
- Key pharmacokinetic parameters including half-life (T 1/2), elimination rate constant (Kel), volume of distribution (VD), clearance (Cl), and area under the curve (AUC) were analyzed.
Main Results:
- No significant differences were observed in the pharmacokinetic parameters (T 1/2, Kel, VD, Cl, AUC) between the two theophylline preparations.
- The micronized theophylline formulation demonstrated a lower incidence of "erratic" behavior compared to the known product.
Conclusions:
- The new micronized slow-release theophylline preparation exhibits comparable pharmacokinetic properties to existing formulations.
- The improved acceptance and reduced erratic behavior suggest the new theophylline product can be used more safely in pediatric asthma patients.
Abstract:
This study compares the pharmacokinetics of two preparations of slow-release theophylline, one of them already known, and the other one a new product (micronized), very well accepted by pediatric patients. Two similar groups of fifteen patients each all of then asthmatic children under ten years of age, were selected and given a single oral dose of 10 mg/kg of one of the preparations. The pharmacokinetic parameters (T 1/2, Kel, VD, Cl and AUC) did not differ between both groups. The new product could further be used more safely, due to its lower incidence of "erratic" behaviour.